A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Catherine S. Spina, Alexander Z. Wei(Columbia University Irving Medical Center), Mark N. Stein(Cornell University), Noor Ani Ahmad(Society of Interventional Radiology), Karie Runcie(Columbia University Irving Medical Center), Shing M. Lee(Columbia University)

Journal of Clinical Oncology

January 29, 2024

10.1200/jco.2024.42.4_suppl.tps240

Cited by 0

Related Papers

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

|The Lancet|2021|3.8k

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

|Journal of Clinical Oncology|2016|1.6k

Bone marrow–on–a–chip replicates hematopoietic niche physiology in vitro

|Nature Methods|2014|450

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

|The Lancet|2020|428

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

|European Journal of Nuclear Medicine and Molecular Imaging|2013|183